Novel Drug Delivery Systems for Releasing Growth Factors to the CNS: Focus on Alzheimer's and Parkinson's Diseases

被引：1

作者：

Herran, E. ^{[1
,2
]}

Igartua, M. ^{[1
,2
]}

Pedraz, J. L. ^{[1
,2
]}

Hernandez, R. M. ^{[1
,2
]}

机构：

[1] Univ Basque Country, UPV EHU, Sch Pharm, Lab Pharmaceut,NanoBioCel Grp, Vitoria 01006, Spain

[2] Biomed Res Networking Ctr Bioengn Biomat & Nanome, Vitoria, Spain

来源：

MINI-REVIEWS IN MEDICINAL CHEMISTRY | 2014年 / 14卷 / 07期

关键词：

Alzheimer's disease; central nervous system; drug delivery systems; GDNF; Parkinson's disease; VEGF; CENTRAL-NERVOUS-SYSTEM; BLOOD-BRAIN-BARRIER; NEURAL STEM-CELLS; NEUROTROPHIC FACTOR; INTRANASAL DELIVERY; GENE-THERAPY; IN-VIVO; BEHAVIORAL RECOVERY; SECRETING CELLS; MOUSE MODEL;

D O I：

10.2174/1389557514666140622205058

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Alzheimer's disease (AD) and Parkinson's disease (PD) represent the most common neurodegenerative disorders and affect more than 35 million people. Due to the limited effectiveness of available treatments in halting the neurodegenerative process, new therapies, such therapies based on growth factors (GFs), have been investigated. Nevertheless, the efficacies of these new treatments depend not only on the application of neurotrophins but also on the approaches used to deliver these proteins such that they can reach the brain. This review summarises the most widely used drug delivery systems (DDSs) for releasing GFs as possible treatments for AD and PD.

引用

页码：557 / 566

页数：10

共 50 条

[41] Nanoparticles for drug delivery in Parkinson's disease
Baskin, Jonathan
Jeon, June Evelyn
Lewis, Simon J. G.
JOURNAL OF NEUROLOGY, 2021, 268 (05) : 1981 - 1994
[42] Immune-Directed Gene Therapeutic Development for Alzheimer's, Prion, and Parkinson's Diseases
Maguire-Zeiss, Kathleen A.
Federoff, Howard J.
JOURNAL OF NEUROIMMUNE PHARMACOLOGY, 2009, 4 (03) : 298 - 308
[43] On a New Paradigm of the Development of Neurodegenerative Diseases by the Example of Alzheimer's Disease and Parkinson's Disease
Litvinenko, I. V.
Lobzin, V. Yu.
ADVANCES IN GERONTOLOGY, 2022, 12 (04) : 386 - 395
[44] Nanotechnology-Driven Therapeutic Innovations in Neurodegenerative Disorders: A Focus on Alzheimer's and Parkinson's Disease
Krsek, Antea
Baticic, Lara
FUTURE PHARMACOLOGY, 2024, 4 (02): : 352 - 379
[45] The role of amyloids in Alzheimer's and Parkinson's diseases
Salahuddin, Parveen
Fatima, Munazza Tamkeen
Uversky, Vladimir N.
Khan, Rizwan Hasan
Islam, Zeyaul
Furkan, Mohammad
INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES, 2021, 190 : 44 - 55
[46] Proposed biochemistry of Parkinson's and Alzheimer's diseases
Robertson, D. S.
MEDICAL HYPOTHESES, 2017, 109 : 131 - 138
[47] Perceptual priming in Alzheimer's and Parkinson's diseases
Koivisto, M
Portin, R
Rinne, JO
NEUROPSYCHOLOGIA, 1996, 34 (05) : 449 - 457
[48] Mitochondria in the pathophysiology of Alzheimer's and Parkinson's diseases
Onyango, Isaac G.
Khan, Shaharyar M.
Bennett, James P., Jr.
FRONTIERS IN BIOSCIENCE-LANDMARK, 2017, 22 : 854 - 872
[49] Sleep Disturbances in Alzheimer's and Parkinson's Diseases
Rothman, Sarah M.
Mattson, Mark P.
NEUROMOLECULAR MEDICINE, 2012, 14 (03) : 194 - 204
[50] Sleep Disturbances in Alzheimer’s and Parkinson’s Diseases
Sarah M. Rothman
Mark P. Mattson
NeuroMolecular Medicine, 2012, 14 : 194 - 204

← 1 2 3 4 5 →